Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer

Durvalumab is an immune checkpoint inhibitor that blocks PD‐L1. Unlike cytotoxic chemotherapy or molecularly targeted agents, immune checkpoint inhibitors occasionally present distinct response patterns, including radiologic pseudoprogression (initial tumor enlargement with subsequent tumor regressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eun Young, Park, Inkeun, Kim, Young Saing, Ahn, Hee Kyung, Lee, Hee Young, Kim, Jeong Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449229/
https://www.ncbi.nlm.nih.gov/pubmed/30734514
http://dx.doi.org/10.1111/1759-7714.12994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449229/
https://www.ncbi.nlm.nih.gov/pubmed/30734514
http://dx.doi.org/10.1111/1759-7714.12994

Ejemplares similares